Cumberland Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Cumberland Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cumberland Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cumberland Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. It acquires, develops, and commercializes branded prescription products that target hospital acute care, gastroenterology, and oncology markets through small, specialized sales teams. The company’s portfolio includes treatments for various conditions, such as Acetadote for acetaminophen poisoning, Caldolor for pain and fever, and Kristalose for constipation. It also offers Omeclamox-Pak for Helicobacter pylori infection, Sancuso for chemotherapy-induced nausea, Vaprisol for hyponatremia, and Vibativ for serious bacterial infections. Cumberland is advancing its pipeline with ifetroban, a selective thromboxane-prostanoid receptor antagonist which has received orphan drug and rare pediatric disease designations for treating cardiomyopathy associated with Duchenne muscular dystrophy. Ifetroban is also being studied for systemic sclerosis, idiopathic pulmonary fibrosis, and other conditions. Cumberland is headquartered in Nashville, Tennessee, the US.
Headquarters
United States of America
Address
1600 West End Avenue, Suite 1300, Nashville, Tennessee, 37203
Website
www.cumberlandpharma.com
Telephone
1 615 2550068
No of Employees
93
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CPIX (NASD)
Revenue (2024)
$44.5M
17.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
56.2%
(2024 vs 2023)
Market Cap*
$95.4M
Net Profit Margin (2024)
XYZ
62.8%
(2024 vs 2023)
* As of and is in US$
Cumberland Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed | Acetadote |
| Acetadote: Acetaminophen Poisoning | Caldolor |
| Caldolor: Pain and Fever | Kristalose |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Asset Disposal | In July, the company sold its branded commercial drug portfolio to Apotex for US$100 million. |
| 2026 | Corporate Changes/Expansions | In March, the company launched a new website for Sancuso, enhancing access to educational resources and clinical information for healthcare professionals and patients regarding chemotherapy-induced nausea and vomiting. |
| 2026 | Regulatory Approval | In February, the company received FDA Fast Track Designation for its ifetroban program targeting heart disease in Duchenne muscular dystrophy patients. |
Competitor Comparison
| Key Parameters | Cumberland Pharmaceuticals Inc | Merck & Co Inc | AbbVie Inc | Takeda Pharmaceutical Co Ltd | Otsuka Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | Japan |
| City | Nashville | Rahway | North Chicago | Chuo-Ku | Chiyoda-Ku |
| State/Province | Tennessee | New Jersey | Illinois | Tokyo | Tokyo |
| No. of Employees | 93 | 75,000 | 57,000 | 47,029 | 6,070 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| A.J. Kazimi | Chairman; Chief Executive Officer | Executive Board | 1999 | 67 |
| John M. Hamm | Vice President; Chief Financial Officer | Senior Management | 2023 | 70 |
| James L. Herman | Vice President - Trade and Distribution; Chief Compliance Officer | Senior Management | - | 70 |
| Chris T. Bitterman | Vice President - Sales and Marketing | Senior Management | 2023 | 60 |
| Ines Macias-Perez | Director - Product Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer